Navigation Links
NewYork-Presbyterian/Columbia physician-scientists present at ACC's 57th Annual Scientific Session
Date:3/28/2008

NEW YORK (March 27, 2008) -- Physician-scientists from NewYork-Presbyterian Hospital/Columbia University Medical Center will present their latest research findings at the American College of Cardiology's 57th Annual Scientific Session in Chicago, March 29 to April 1. Among the most significant presentations are the following:

Drug-Eluting Stents Versus Bare-Metal Stents for Transplant Allograft Vasculopathy

Dr. Jeffrey Moses Director of the Center for Interventional Vascular Therapy and director of the Cardiac Catheterization Lab at NewYork-Presbyterian Hospital/Columbia University Medical Center and professor of medicine at Columbia University College of Physicians and Surgeons

Heart transplant patients are more vulnerable to accelerated arteriosclerosis in their transplanted heart than the general population. In one of the largest studies of its kind, NewYork-Presbyterian/Columbia researchers found that drug-eluting stents were able to better keep arteries open and prevent narrowing than bare-metal stents. However, mortality rates for interventions were equal.


The Impact of Mandatory Angiographic Follow-up on the One-Year Clinical and Angiographic Results From Endeavor IV: A Randomized Comparison of the Endeavor Drug (ABT-578) Eluting Stent System vs. Taxus in De Novo Native Coronary Lesions

Dr. Martin B. Leon Associate director of the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center and professor of medicine at Columbia University College of Physicians and Surgeons. He is founder and chairman emeritus of the Cardiovascular Research Foundation in New York City.

This presentation will look at follow-up using angiograms and clinical outcomes on patients in the Endeavor IV study, which compares the Endeavor drug-eluting stent with the Taxus drug-eluting stent. The results indicate that clinical follow-up may be more meaningful in determining the true patient value of drug-eluting stents in preventing restenosis, the closing or narrowing of the previously-opened artery.


Safety and Effectiveness of Bivalirudin in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty: The HORIZONS AMI Trial

Impact of Baseline Renal Function on the Safety and Effectiveness of Bivalirudin in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty: The HORIZONS AMI Trial

Impact of Advanced Age on the Safety and Effectiveness of Bivalirudin in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty: The HORIZONS AMI Trial

Impact of Diabetes Mellitus on the Safety and Effectiveness of Bivalirudin in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty: The HORIZONS AMI Trial

Is Diabetes a Risk Factor for Restenosis and Adverse Clinical Outcomes After Paclitaxel-Eluting Stent Implantation: Pooled Analysis of the TAXUS IV and TAXUS V Trials

Dr. Gregg W. Stone Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center and professor of medicine at Columbia University College of Physicians and Surgeons. He is also chairman of the Cardiovascular Research Foundation in New York City.

Dr. Stone will present new findings from the HORIZONS AMI trial, which is evaluating the drug bivalirudin for heart attack patients undergoing angioplasty. Last year, investigators reported that the therapy reduces risk of death compared with the standard treatment. New findings look at several subsets, including older patients and patients with diabetes, finding bivalirudin also effective for these groups.

In addition, Dr. Stone will present findings from the TAXUS trials looking at the risk of restenosis and other negative outcomes in patients with diabetes with the Taxus drug-eluting stent.


'/>"/>

Contact: Bryan Dotson
brd9005@nyp.org
212-305-5587
New York- Presbyterian Hospital/Columbia University Medical Center
Source:Eurekalert

Related medicine news :

1. CVS Caremark Presents at NCOA-ASA Conference on Companys Commitment to Recruiting and Retaining Mature Workers
2. Gen-Probe to Webcast Presentation at Leerink Swann Molecular Diagnostics Conference
3. Clarient to Present at the B. Riley & Co. 9th Annual Las Vegas Investor Conference
4. Accurays CFO to Present at B. Riley & Company Ninth Annual Investor Conference
5. Rigel to Present at 8th Annual Fortis Bank Biotechnology Conference
6. Bionovo to Present at the Cambria Capital Investor Meeting
7. UC Irvine researchers present latest findings at emergency medicine forum
8. BD to Present at the Leerink Swann Molecular Diagnostics Roundtable Conference
9. RNR Public Relations Presents Perfect April Fools Day Feature Opportunity
10. Health Fitness to Present at B. Riley & Co. 9th Annual Las Vegas Investor Conference
11. Gourmetceuticals to Present Data from Four Studies at Experimental Biology 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... ... March 01, 2017 , ... ... announce the release of its 2017 update to Compass, the popular online ... physician advisors. , Suitable for standardizing both new-hire on-boarding and annual competency-validation, ...
(Date:3/1/2017)... ... , ... Expert on international living and leading a healthy lifestyle, Alina Reyzelman, ... & Go app is the ultimate strategic compass that helps users to achieve goals ... people to work smarter, not harder, that's why Time & Go app provides tools ...
(Date:3/1/2017)... ... ... is Comfort for the Soul”: a loving account of a very special dog, the ... soul-healing comfort provided by God’s presence in the face of deep sorrow. “There is ... dog-loving medical professional whose work takes her to remote areas in the American Northwest, ...
(Date:3/1/2017)... ... ... to the Law of God”: a message about the revelation of God to our dark ... God” is the creation of published author Brent Chrishon, a former sales professional who left ... dedicated their lives to spreading God’s word both in the United States and abroad. , ...
(Date:2/28/2017)... ... February 28, 2017 , ... Answering strong demand for its medical ... will open a branch office in the Soma neighborhood in San Francisco on March ... factors, FDA regulatory and software systems architecture subject matter experts. , Orthogonal serves a ...
Breaking Medicine News(10 mins):
(Date:3/1/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The latest research Acute Myeloid Leukemia Drugs Price ... in the global Acute Myeloid Leukemia market. This research ... find out how the marketed products for Acute Myeloid Leukemia are ...
(Date:3/1/2017)... El mismo sistema se mostrará en el Congreso Europeo de Radiología (CER) ... ... The open MRI scanner - MROpen engineered and developed by Paramed in the ... Paramed ... primera en Gales. El escáner se localizará en el nuevo centro del European Scanning Centre ...
(Date:2/28/2017)... 2017 Persistence Market Research tables a ... market in a new publication named, "Dysphagia Management ... the name suggests, we have forecasted the global ... on the basis of the various market segments ... opportunities available to all the companies operating in ...
Breaking Medicine Technology: